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CASE REPORT
New psychoactive substances (NPS) escape routine drug testing: a case
report of phenibut
Torben Breindahla , Peter Hinderssona and Andreas Kimergårdb
aDepartment of Clinical Biochemistry, North Denmark Regional Hospital, Hjørring, Denmark; bNational Addiction Centre, Institute of
Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
ABSTRACT
Phenibut (bphenyl caminobutyric acid) is licensed for use as a medicine in countries out-
side of the European Union (EU), but has also been sold as a “food supplement” from online
shops to the general public in the EU. We present a case of phenibut use in a 25-year-old
female undergoing alcohol and drug addiction treatment. She reported using phenibut, which
she had purchased readily over the internet as a “food supplement.” Our clinical laboratory
located in a hospital in the same region received urine samples for analysis which confirmed
ingestion of phenibut. Identifying and responding to new psychoactive substances (NPS) emerg-
ing on the drug markets poses a challenge to clinical and forensic drug testing. A comprehen-
sive laboratory analysis approach can identify the use of multiple NPS, including those used as






The growing number of new psychoactive substances
(NPS) poses a challenge to public health and drug
regulation in the European Union (EU) [1,2]. Drugs
found on the NPS drug markets which have legitim-
ate uses as medicines in countries outside of the EU
complicate the situation. These include the anxiolytic
drug phenibut (b phenyl caminobutyric acid).
Phenibut is licensed to treat alcohol dependence in
Russia, but has also been detected in the EU where it
is sold as a “food supplement” [3].
Amongst EU countries, phenibut was first detected
as an NPS in Sweden and reported for the first time
in 2012 to the EU Early Warning System operated by
the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) [2]. Phenibut is used for its
psychoactive effects, as a nootropic (“smart drug”)
and to improve sleep [3,4]. Reported symptoms of
phenibut withdrawal are both somatic (such as
insomnia, convulsions and tachycardia) and psycho-
logical (such as craving and anxiety) [3]. According
to cases reported to the Dutch Poisons Information
Center patients ingested between 1 and 10 grams of
phenibut daily and presented with a range of adverse
events including seizures and loss of consciousness
[5]. Reported symptoms of acute toxicity to phenibut
overdose include agitation and reduced state of con-
sciousness that may require supportive care and
intubation [6,7].
This article presents a case report of phenibut
ingestion, analytically confirmed, to highlight the
presence of NPS in Denmark and discuss the benefits
of a comprehensive approach to drug testing.
Case
A female patient, aged 25 years, attending alcohol and
drug addiction treatment in a service in the North
Denmark Region, reported use of phenibut to mem-
bers of staff (initially reported in 2018). She pur-
chased the phenibut product online, where it was sold
as a “food supplement.” Disclosure of phenibut use
occurred voluntarily as part of the assessment com-
pleted by the staff member in charge of treatment.
The unfamiliarity of phenibut and its associated
health and social risks (phenibut was new to the staff
member) prompted further investigation. As part of
this investigation we were contacted at the clinical
laboratory, North Denmark Regional Hospital for
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possible confirmation of phenibut exposure and for
help interpreting the results. After including phenibut
in our drug testing programme conducted by liquid
chromatography and tandem mass spectrometry (LC-
MS/MS), we confirmed its presence in two urine sam-
ples obtained from the patient and delivered to our
laboratory for testing. The first sample was positive
for phenibut and alprazolam; the second for phenibut,
oxazepam and gamma-hydroxybutyrate (GHB). This
information was fed back to the drug treatment ser-
vice and used for diagnostic and care planning illus-
trating the collaborative partnerships between hospital
and addiction treatment in the region.
Discussion
To the best of our knowledge, this is the first pub-
lished case report of confirmed phenibut use in
Denmark. Publication as well as notification of NPS
to the EU Early Warning System ensures that poten-
tial threats from new drugs are detected, assessed and
responded to. Active substances used in medicines
(such as phenibut) should also be reported.
The presence of a large number of NPS creates
challenges for alcohol and drug addiction treatment
that raise concerns for public health. The patient
described here provided two urine samples testing
positive for phenibut, GHB and benzodiazepines.
H€ogberg et al. reported phenibut use in a patient also
with concomitant consumption of benzodiazepines
and a history of opioid addiction [4]. LC-MS/MS test-
ing at our laboratory for multiple drugs enabled staff
members in the drug treatment service to establish
substance intake and obtain information about
unfamiliar NPS used to improve treatment plans.
Others have reported that comorbid dependence
on phenibut and benzodiazepines have successfully
been treated with baclofen (also a GABA receptor
agonist) (Figure 1) [3]. Unambiguous identification of
phenibut, achieved through partnerships between
drug treatment services and clinical laboratories that
offer comprehensive drug screening, can guide the
decision to initiate the prescribing of substitution
therapy, confirm treatment compliance, and monitor
further use of phenibut [8].
The effects of phenibut withdrawal appear similar
to those associated with benzodiazepine withdrawal
[3,4]. A similar situation exists in treating drug over-
doses where CNS depression caused by phenibut can
result in clinical effects that are similar to those of
opioid overdose. In one case report published by
Sankary et al., a patient who was taken to the
Emergency Department after phenibut ingestion was
treated with intravenous naloxone although naloxone
is an opioid receptor antagonist with no effect in the
treatment of phenibut overdose (a GABA receptor
agonist) [9]. Waiting for the results of LC-MS/MS
testing, which has a turnaround time of approxi-
mately 2 days in our laboratory, should not lead to
unnecessary delays in the initiation of emergency
care. Rather, results from LC-MS/MS analysis can
improve diagnosis and follow-up care. At referral to
addiction treatment, if deemed necessary and appro-
priate, accurate reports of ingested substances can be
used during the initial assessment and to establish
treatment plans. By contrast, relying on reports of
patients who have ingested “food supplements”
obtained from the internet presents a problem given
the discrepancies between the ingredients declared on
the label and the actual chemical contents and quanti-
ties (including in “food supplements” containing phe-
nibut) [10].
Phenibut is promoted for stress reduction and as a
mood enhancer according to product declarations [7].
Printed materials in the self-help genre can be
ordered online, which describe how “to take phenibut
safely” (Figure 2) [11]. While such information is use-
ful in understanding the marketing of NPS, detection
using LC-MS/MS analysis plays a crucial role in
responding in a timely and appropriate manner to
threats from new drugs appearing on the market. In
Figure 1. Structures of (a) phenibut (b phenyl
caminobutyric acid); (b) baclofen (b(4-chlorophenyl)c
 aminobutyric acid); and (c) c aminobutyric acid (GABA).
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the current circumstances of availability and use of a
variety of NPS, LC-MS/MS analysis – unlike most
immunoassays – will simultaneously test for many
drugs to improve treatment by correctly identifying
the ingested substances. Compared to immunoassays,
LC-MS/MS has lower limits of detection, lower costs
of screening per specimen, and identifies a greater
number of substances [12].
However, phenibut and many other NPS are not
generally included in routine clinical drug testing pro-
grams in Denmark. Further, the widespread use of
immunoassays and practices such as only forwarding
samples to a laboratory for confirmatory analysis
when pre-screening with immunoassays are positive
hinder detection of NPS [13]. After including pheni-
but in our multi-methods for routine drug testing, we
have detected positive samples from a patient in pri-
mary care and one in prison suggesting its use across
different groups of people taking drugs. Without a con-
tinuous update of drug testing methods many NPS are
likely to remain undetected, which makes it difficult to
fully characterise the NPS situation in Denmark.
In summary, a comprehensive laboratory analysis
approach can identify the use of multiple NPS includ-
ing those used as medicines. Conversely, the use of
immunoassays represents a traditional and yet obso-
lete approach that is no longer adequate nor safe for
the public in terms of dealing with the current chal-
lenges in the NPS landscape [13].
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